Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced the upcoming presentation of full 9-month results from the HELIOS-A Phase 3 study of vutrisiran at the AAN Virtual Annual Meeting, scheduled for April 17-22. Vutrisiran is an investigational RNAi therapeutic for hereditary ATTR amyloidosis. This milestone follows the positive topline results previously reported in January. The company aims to submit a U.S. regulatory filing for vutrisiran in early 2021. The presentation will also feature updates from ongoing studies on ONPATTRO and GIVLAARI.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has published its first Corporate Responsibility (CR) Summary, outlining its environmental, social, and governance (ESG) standards. Key commitments include increasing minority participation in clinical trials, promoting female leadership, and enhancing employee support programs. The report emphasizes Alnylam's dedication to sustainability and accountability, led by a new CR Committee. It marks a significant step toward the company's vision of becoming a top 5 biotech firm while adhering to its core values.
Soleo Health has joined the treatment center directory for GIVLAARI (givosiran), enabling it to administer this FDA-approved therapy for adults with Acute Hepatic Porphyria (AHP). GIVLAARI is the first approved treatment for AHP, which causes the buildup of neurotoxins. Soleo Health offers injections in-home or at its infusion centers, utilizing its experience in specialty pharmacy. This partnership enhances Soleo's portfolio in treating rare diseases and utilizes SoleMetrics to collect valuable patient data over time.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at three upcoming virtual conferences. The events are the Cowen 41st Annual Healthcare Conference on March 1 at 2:40 pm ET, the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 am ET, and the Barclays Global Healthcare Conference on March 10 at 1:15 pm ET. Each presentation will have a live audio webcast available on the Company’s website, with replays accessible within 48 hours.
Alnylam specializes in RNA interference therapeutics aimed at treating various severe diseases.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a company overview presentation at the 10th Annual SVB Leerink Global Healthcare Conference, scheduled for February 25, 2021, at 11:20 am ET. A live audio webcast will be accessible on the Investors section of Alnylam's website, with a replay available 48 hours post-event.
Alnylam is a leader in RNA interference therapeutics, developing innovative medicines for various diseases. Its current products include ONPATTRO, GIVLAARI, and OXLUMO, among others.
Alnylam Pharmaceuticals (Nasdaq: ALNY) reported strong financial results for Q4 and full year 2020, showcasing significant growth in product revenues amid regulatory approvals. ONPATTRO achieved $306 million in annual revenue, marking over 80% growth from 2019, while GIVLAARI brought in $55 million in its launch year. The company expects combined 2021 product revenues between $610 million and $660 million, indicating over 75% growth from 2020. Key developments included positive Phase 3 results for vutrisiran and the launch of OXLUMO. Alnylam anticipates continued expansion and product launches in 2021.
Alnylam Pharmaceuticals (Nasdaq: ALNY) is set to announce financial results for Q4 and the full year ending December 31, 2020, on February 11, 2021. The conference call will occur at 8:30 am ET, discussing performance and future expectations. Investors can access the live audio webcast through their website. Alnylam, founded in 2002, focuses on RNA interference therapeutics, including products like ONPATTRO, GIVLAARI, and OXLUMO. The company’s innovative pipeline aims to address rare and common diseases, underpinned by a robust financial outlook and strategic growth initiatives.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its 5-year strategy named Alnylam P5x25, aiming to be among the top 5 biotech firms by market capitalization. Key goals include reaching over 0.5 million patients on its RNAi therapeutics, marketing at least 6 products, and achieving ≥40% revenue CAGR through 2025. Preliminary Q4 2020 revenues for ONPATTRO and GIVLAARI were approximately $90 million and $22 million, respectively, marking significant growth and strong demand for its therapies.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic for hATTR amyloidosis. The study met primary and secondary endpoints, showing significant improvements in neurologic impairment and quality of life at 9 months, with a favorable safety profile. The company plans to submit a New Drug Application (NDA) to the FDA in early 2021 and expects additional regulatory filings globally. Vutrisiran's promising results position it as a potential treatment for this serious condition.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:20 am ET, discussing unaudited fourth quarter and full year 2020 revenues. A Q&A breakout session will follow at 8:40 am ET. Investors can access a live audio webcast on the company's website, with a replay available within 48 hours. Alnylam is a leader in RNA interference therapeutics, working to develop innovative treatments for rare diseases.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
